These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 33722571)

  • 1. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
    Hong T; Lei G; Chen X; Li H; Zhang X; Wu N; Zhao Y; Zhang Y; Wang J
    Redox Biol; 2021 Jun; 42():101928. PubMed ID: 33722571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
    Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R
    Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
    Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G
    Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors.
    Xie X; Chen C; Wang C; Guo Y; Sun B; Tian J; Yan J; Li D; Chen G
    Redox Biol; 2024 Oct; 76():103350. PubMed ID: 39265497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of KLF5 sensitizes
    Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
    Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 8. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition.
    Li Y; Cen Y; Fang Y; Tang S; Li S; Ren Y; Zhang H; Lu W; Xu J
    ACS Nano; 2022 Aug; 16(8):12786-12800. PubMed ID: 35920396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism.
    Miao H; Meng H; Zhang Y; Chen T; Zhang L; Cheng W
    Cell Death Differ; 2024 Apr; 31(4):497-510. PubMed ID: 38374229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
    Wang D; Wang M; Jiang N; Zhang Y; Bian X; Wang X; Roberts TM; Zhao JJ; Liu P; Cheng H
    Oncotarget; 2016 Mar; 7(11):13153-66. PubMed ID: 26909613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors.
    Cui Y; Li Y; Xu Y; Liu X; Kang X; Zhu J; Long S; Han Y; Xue C; Sun Z; Du Y; Hu J; Pan L; Zhou F; Xu X; Li X
    Redox Biol; 2024 Oct; 76():103304. PubMed ID: 39153252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
    Tang S; Shen Y; Wei X; Shen Z; Lu W; Xu J
    Cell Death Dis; 2022 Sep; 13(9):826. PubMed ID: 36163324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
    Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES
    PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    Cho HY; Kim YB; Park WH; No JH
    Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
    Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
    Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.
    Lei G; Mao C; Horbath AD; Yan Y; Cai S; Yao J; Jiang Y; Sun M; Liu X; Cheng J; Xu Z; Lee H; Li Q; Lu Z; Zhuang L; Chen MK; Alapati A; Yap TA; Hung MC; You MJ; Piwnica-Worms H; Gan B
    Cancer Discov; 2024 Aug; 14(8):1476-1495. PubMed ID: 38552003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.